Aubin N’GUESSAN, Ludovic Akonan, Désiré MELEDJE, Hermann N’Guessan, Gabin Placide ALLANGBA, Logbo MOUSSE, Nahossé Ziao, Melalie Keita, Raymond KRE & Eugene Megnassan·Journal of Pharmaceutical Research International·2025
This study developed a random forest (RF) model based on a large and diverse dataset to classify whether organic chemicals or drugs are respiratory toxicants. Indeed, the concerns regarding drug-induced respiratory remain a major cause of drug candidate failure in clinical trials...
Open access
Research Article10.9734/jpri/2025/v37i127774
Eric Ziki, Ludovic Akonan, Koffi Charles Kouman, Brice Dali, Eugene Megnassan, Rita Kakou-Yao, Abodou Jules Tenon, Vladimir Frecer & Stanislav Miertus·Journal of Pharmaceutical Research International·2023
Background: We have carried out virtual design of coumarinyl-substituted sulfonamides (CSAM) analogs as inhibitors of human carbonic anhydrase II (hCA II) endowed with favorable predicted pharmacokinetic profiles and potential therapeutic effects against glaucoma. Methods: modify...
Open access
Research Article10.9734/jpri/2023/v35i247424
Issouf Soro, Manchondenin Soro, Ludovic Akonan, Niaré Adama, Boris Davy Bekono, Raymond Kre N’guessan & Eugene Megnassan·Asian Journal of Chemical Sciences·2026
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with cholinergic dysfunction, and butyrylcholinesterase (BuChE) becomes increasingly relevant as disease pathology progresses. This study aimed to design sulfenylated 5-aminopyrazole (APS) analogues as potential...
Open access
Research Article10.9734/ajocs/2026/v16i5478
We report here the design of new inhibitors against human monoamine oxidase (hMAO-B) as potential treatment of Parkinson’s disease. We have completed computer-aided molecular design of MAO-B inhibitors by In situ modification of the reference crystal structure of 7-(3-chlorobenzy...
Open access
Research Article10.9734/jpri/2024/v36i107592